Global Injectable Suspension Budesonide Market Outlook 2022

Budesonide Inhalation Suspension should be administered via jet nebulizer connected to an air compressor with an adequate air flow, equipped with a mouthpiece or suitable face mask. Ultrasonic nebulizers are not suitable for the adequate administration of Budesonide Inhalation Suspension and, therefore, are not recommended.

The global Injectable Suspension Budesonide market was valued at US$ million in 2020 and is expected to reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.
This report focuses on Injectable Suspension Budesonide volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Injectable Suspension Budesonide market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Injectable Suspension Budesonide Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.


Segment by Type
0.5mg
1mg


Segment by Application
Respiratory Disease Treatment
Nose Disease Treatment
Inflammatory Bowel Disease Treatment
Other


By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE


By Company
AstraZeneca
Teva
Mylan
Sandoz
Cosmo Pharmaceuticals
Salix
Chiesi Farmaceutici
Orion Corporation
Cipla
Synmosa Biopharma
Lunan Better Pharma
Shanghai Sine Promod